Profile data is unavailable for this security.
About the company
HOB Biotech Group Corp Ltd is a China-based company primarily engaged in the research and development, production and sales of in vitro diagnostic reagents. The Company provides two categories of products: allergy testing products and self-immune testing products. Its detection techniques include qualitative detection techniques such as enzyme-linked immunosorbent assay, and quantitative detection techniques such as enzyme-linked immunoassay capture method and nano-magnetic particle chemiluminescence method. The brands of allergy testing products include Oboke, Fubok, Shibok and Shibok Plus. The self-immune testing product brands include Norbok and Nabok. It is also engaged in the provision of reagent supporting testing instruments and others. The Company conducts its businesses in the domestic market.
- Revenue in CNY (TTM)399.23m
- Net income in CNY45.58m
- Incorporated2009
- Employees550.00
- LocationHOB Biotech Group Corp LtdBuilding C10, Bio-Nano Park218 Xinghu Street, Industrial ParkSUZHOU 215123ChinaCHN
- Phone+86 51 269561996
- Fax+86 51 262956652
- Websitehttp://www.hob-biotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Nanfang Medical Co Ltd | 513.15m | -152.60m | 1.17bn | 858.00 | -- | 2.45 | -- | 2.27 | -0.5281 | -0.5281 | 1.77 | 1.63 | 0.3732 | 1.68 | 3.23 | 598,071.00 | -11.09 | -1.09 | -26.74 | -2.00 | 7.70 | 20.14 | -29.71 | -1.91 | 0.3585 | -12.20 | 0.5143 | -- | 10.03 | 4.57 | -906.35 | -- | -3.18 | -- |
| CareRay Digital Medical Technology CoLtd | 276.59m | 23.25m | 1.18bn | 252.00 | 50.94 | 1.39 | -- | 4.28 | 0.2638 | 0.2638 | 3.14 | 9.70 | 0.3037 | 1.47 | 4.51 | 1,097,595.00 | 2.56 | 6.65 | 2.73 | 7.37 | 39.84 | 41.17 | 8.41 | 15.64 | 11.20 | -- | 0.006 | 27.61 | 33.81 | 5.17 | 374.05 | -20.74 | 77.38 | -- |
| Touchstone International Medi Sci Co Ltd | 254.39m | 46.96m | 1.33bn | 243.00 | 26.18 | 2.32 | -- | 5.23 | 0.6264 | 0.6264 | 3.36 | 7.08 | 0.4371 | 3.37 | 28.08 | 1,046,885.00 | 8.07 | 10.09 | 8.66 | 10.82 | 55.49 | 57.59 | 18.46 | 20.17 | 9.45 | -- | 0.0031 | 24.66 | 9.31 | 16.34 | 9.53 | 15.39 | -2.39 | -- |
| Thalys Medical Technology Group Corp | 2.05bn | -140.51m | 1.35bn | 1.41k | -- | 1.12 | -- | 0.6599 | -0.8515 | -0.8515 | 11.25 | 5.97 | 0.5812 | 3.88 | 1.24 | 1,456,036.00 | -3.86 | -0.8933 | -7.08 | -1.62 | 19.24 | 22.12 | -6.63 | -1.49 | 1.47 | -1.09 | 0.4509 | -- | -13.10 | 8.77 | -2.69 | -- | -19.20 | -- |
| HOB Biotech Group Corp Ltd | 399.23m | 45.58m | 1.56bn | 550.00 | 34.28 | 1.91 | -- | 3.91 | 0.7228 | 0.7228 | 6.33 | 12.97 | 0.4194 | 1.40 | 10.29 | 725,874.40 | 4.79 | 9.94 | 5.64 | 12.10 | 61.81 | 65.30 | 11.42 | 19.53 | 1.08 | -- | 0.0936 | 32.59 | 23.10 | 14.38 | 13.64 | 3.34 | 46.19 | -- |
| Guangzhou Jet Bio-Filtration Co Ltd | 487.09m | 51.76m | 1.62bn | 1.09k | 30.41 | 1.40 | -- | 3.33 | 0.3805 | 0.3805 | 3.62 | 8.26 | 0.3051 | 3.08 | 5.08 | 446,463.00 | 3.26 | 9.35 | 3.48 | 10.39 | 31.00 | 36.76 | 10.69 | 17.89 | 6.86 | 9.15 | 0.2319 | 29.64 | -24.06 | 17.42 | -60.34 | -8.02 | 47.32 | -- |
| Allgens Medical Technology Co Ltd | 226.03m | 42.66m | 1.85bn | 202.00 | 42.67 | 1.30 | -- | 8.19 | 0.3199 | 0.3199 | 1.70 | 10.47 | 0.151 | 1.42 | 3.98 | 1,118,950.00 | 2.78 | 7.62 | 2.90 | 8.30 | 80.57 | 83.60 | 18.40 | 39.05 | 35.91 | -- | 0.0354 | 5.25 | -7.68 | 12.86 | -43.04 | 10.46 | -26.12 | -- |
| Nanjing Medlander Medical Tech Co Ltd | 336.04m | 93.72m | 2.28bn | 481.00 | 24.34 | 1.65 | -- | 6.78 | 0.9354 | 0.9354 | 3.37 | 13.78 | 0.2194 | 1.88 | 18.91 | 698,624.50 | 6.35 | -- | 6.93 | -- | 73.32 | -- | 28.95 | -- | 8.63 | -- | 0.0104 | -- | -9.57 | -- | -26.19 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to HOB Biotech Group Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
10.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Broad Fund Management Co. Ltd.as of 31 Dec 2023 | 545.44k | 4.25% |
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 411.83k | 3.21% |
| CPIC Fund Management Co. Ltd.as of 31 Dec 2023 | 261.08k | 2.03% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 70.40k | 0.55% |
| Hui'an Fund Management Co. Ltd.as of 30 Jun 2023 | 24.00k | 0.19% |
| Manulife TEDA Fund Management Co., Ltd.as of 31 Dec 2023 | 15.57k | 0.12% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023 | 15.15k | 0.12% |
| Lion Fund Management Co., Ltd.as of 31 Dec 2023 | 5.33k | 0.04% |
| JX Asset Management Co.,Ltdas of 30 Jun 2023 | 5.00k | 0.04% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 4.63k | 0.04% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
